Companion Diagnostic Development

Companion Diagnostic Development

At Almac we have developed the experience and expertise to enable the discovery, validation and commercialisation of companion diagnostic strategies.

We can support the development of companion diagnostics from early biomarker discovery in the pre-clinical phase to the development and delivery of a diagnostic test.

The solutions we offer include:

  • Pre-clinical biomarker discovery
  • Assay development
  • Tissue migration studies
  • Platform migration studies
  • Biomarker validation
  • Biomarker clinical trial management
  • Sample analysis in our CLIA lab
  • Test development
  • Regulatory support
  • Commercialisation partners for test distribution

To learn more, please click here to contact us.

Video:

Almac Advantage

Internal Biomarker Discovery

Our internal biomarker discovery team are focused on the discovery of prognostic and predictive tests as well as tests for improved diagnosis of cancer and developing technical solutions to support this work.

Proprietary Technology

We have our own portfolio of proprietary discovery arrays Xcel™ for studies involving multiple and cross disease areas and Cancer DSA® for specific disease indications.

Discovery to Delivery

At Almac we have the capacity to work with you from early biomarker discovery right through to delivery of tests. Our CLIA registered lab enables us to use novel tests to stratify and enrich prospective clinical trails.

Flash replacement image